09995.HK香港交易所 · 主板 Main
Remegen 榮昌生物
Pharmaceuticals and Biotechnology 药品及生物科技
HK$71.20−HK$1.70 · −2.33%
Open 开盘
HK$72.90
High 最高
HK$73.05
Low 最低
HK$71.00
Prev Close 昨收
HK$72.90
Volume 成交量
219.0万股
Turnover 成交额
HK$1.57亿
Mkt Cap 总市值
HK$402亿
P/E 市盈率
51.1×
Recent Activity 近期动态All Filings 全部公告 →
8 significant filings since 1 Jun 2026: 6 on buyback, 1 on earnings pre-announcement and 1 on new listing. The latest, on 2 Sep 2026: 海外监管公告 - 关于2026年第一次以集中竞价交易方式回购公司股份的进展公告.
自 1 Jun 2026 起有 8 份重大公告：buyback 6 份、earnings pre-announcement 1 份、new listing 1 份。最新一份（2 Sep 2026）：海外监管公告 - 关于2026年第一次以集中竞价交易方式回购公司股份的进展公告。
Price History 价格走势
5 sessions 个交易日, 22 Sep to 28 Sep 2026 · Live one-minute prices 实时分钟价格 · High 最高 HK$81.20 · Low 最低 HK$71.00 · −2.33% on the previous close of HK$72.90 较昨收72.0074.0076.0078.0080.00
Volume 成交量
22.2万
22 Sep23 Sep24 Sep25 Sep28 Sep
Against Its Own History 与自身历史比较
Price-to-Earnings Ratio
市盈率
The share price divided by earnings per share. A P/E of 20 means the price equals twenty years of the company’s current earnings per share.
股价除以每股收益。市盈率 20 倍，意味着股价相当于公司当前二十年的每股收益。 Lower is cheaper, but a low P/E often means the market expects profits to fall.
越低越便宜，但过低的市盈率往往意味着市场预期盈利将下滑。
股价除以每股收益。市盈率 20 倍，意味着股价相当于公司当前二十年的每股收益。 Lower is cheaper, but a low P/E often means the market expects profits to fall.
越低越便宜，但过低的市盈率往往意味着市场预期盈利将下滑。
51.1×
No history to compare 无历史可比
Price-to-Book Ratio
市净率
The share price divided by book value per share. Book value is what the company owns after debts, so below 1.0 the market values the business at less than its balance sheet.
股价除以每股净资产。净资产是公司扣除负债后的家底，低于 1 倍说明市场给公司的估值低于其账面价值。 It is useful for banks and asset-heavy industries and tells you little about software companies.
适用于银行和重资产行业，对软件公司参考意义不大。
股价除以每股净资产。净资产是公司扣除负债后的家底，低于 1 倍说明市场给公司的估值低于其账面价值。 It is useful for banks and asset-heavy industries and tells you little about software companies.
适用于银行和重资产行业，对软件公司参考意义不大。
—
No history to compare 无历史可比
Period by Period 逐期
| Period 报告期 | Close at Period End 期末收盘 | TTM EPS 滚动每股收益 |
Price-to-Earnings Ratio
市盈率
The share price divided by earnings per share. A P/E of 20 means the price equals twenty years of the company’s current earnings per share. 股价除以每股收益。市盈率 20 倍，意味着股价相当于公司当前二十年的每股收益。 Lower is cheaper, but a low P/E often means the market expects profits to fall. 越低越便宜，但过低的市盈率往往意味着市场预期盈利将下滑。 | BPS 每股净资产 |
Price-to-Book Ratio
市净率
The share price divided by book value per share. Book value is what the company owns after debts, so below 1.0 the market values the business at less than its balance sheet. 股价除以每股净资产。净资产是公司扣除负债后的家底，低于 1 倍说明市场给公司的估值低于其账面价值。 It is useful for banks and asset-heavy industries and tells you little about software companies. 适用于银行和重资产行业，对软件公司参考意义不大。 |
|---|---|---|---|---|---|
| 30 Jun 2026 中报 | HK$74.30 | ¥10.44 | — | ¥14.73 | — |
| 31 Mar 2026 一季报 | HK$95.80 | ¥2.33 | — | ¥6.96 | — |
| 31 Dec 2025 年报 | HK$72.00 | ¥1.29 | — | ¥6.39 | — |
| 30 Sep 2025 三季报 | HK$117.20 | −¥1.75 | — | ¥4.11 | — |
| 30 Jun 2025 中报 | HK$54.45 | — | — | ¥4.18 | — |
| 31 Mar 2025 一季报 | HK$23.70 | −¥2.54 | — | ¥3.14 | — |
| 31 Dec 2024 年报 | HK$14.40 | −¥2.73 | — | ¥3.52 | — |
| 30 Sep 2024 三季报 | HK$17.10 | — | — | ¥4.20 | — |
| 31 Mar 2024 一季报 | HK$27.15 | — | — | ¥5.45 | — |
Consensus Forward EPS 机构预测每股收益
No broker forecasts for this company yet 暂无机构预测
Not Computed 未计算
- Dividend Yield 股息率
- Free Cash Flow 自由现金流
- EV/EBITDA